<div id="readability-page-1"><p>J.P. Morgan analyst Lisa Gill has maintained their bullish  stance on <span>CI</span> stock, giving a Buy rating on May 13.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Lisa Gill has given his Buy rating due to a combination of factors that highlight Cigna’s strong and flexible capital position. The company generates substantial free cash flow, which not only supports internal growth initiatives, but also enables consistent capital returns to shareholders through dividends and share repurchases while Evernorth transitions to a rebate‑free PBM model.</p> <p>Cigna has rapidly reduced leverage following the Express Scripts acquisition and now operates near its long‑term debt‑to‑capital target, supported by solid investment‑grade ratings. Management’s plan to allocate future cash flows in a balanced manner, emphasizing steady dividend growth, ongoing buybacks, and disciplined, accretive M&amp;A, underpins a robust outlook for double‑digit adjusted EPS growth, making the stock attractive at current levels.</p> <p>In another report released on May 13, Bank of America Securities also reiterated a Buy rating on the stock with a $378.00 price target.</p></div>

<p>J.P. Morgan analyst Lisa Gill has maintained a Buy rating on Cigna (CI) due to its strong free cash flow, reduced leverage, and a positive outlook for double-digit EPS growth. The company’s solid capital position supports dividends and share repurchases, while management plans balanced cash flow allocation. Bank of America Securities also reiterated a Buy rating with a $378 price target.</p>

- Analyst Lisa Gill from JPMorgan maintains a bullish outlook on Cigna Corporation (CI), assigning a buy rating on May 13.  
- She highlights Cigna's strong capital position, significant free cash flow, and a balanced future cash flow allocation strategy that supports dividend growth and stock buybacks.  
- Additionally, Bank of America Securities reaffirmed a buy rating on the same day, setting a target price of $378.00 for the stock.

Tip Ranks

Cigna

JPMorgan Chase

Bank of America

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Cigna Earns Buy Rating on Strong Free Cash Flow, Deleveraged Balance Sheet, and Double-Digit EPS Growth Outlook